Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Accumulated Expenses (2023)

Kairos Pharma filings provide 1 years of Accumulated Expenses readings, the most recent being $43000.0 for Q4 2023.

  • On a quarterly basis, Accumulated Expenses changed N/A to $43000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $43000.0, a N/A change, with the full-year FY2023 number at $43000.0, changed N/A from a year prior.
  • Accumulated Expenses hit $43000.0 in Q4 2023 for Kairos Pharma.
  • In the past five years, Accumulated Expenses ranged from a high of $43000.0 in Q4 2023 to a low of $43000.0 in Q4 2023.